{
    "clinical_study": {
        "@rank": "117702", 
        "arm_group": [
            {
                "arm_group_label": "Gefitinib and Pemetrexed/cisplatin", 
                "arm_group_type": "Experimental", 
                "description": "Gefitinib 250mg is Taken Orally on day 4-28,combined Pemetrexed/cisplatin chemotherapy on day 1-3, every 28 days"
            }, 
            {
                "arm_group_label": "Gefitinib mono-therapy", 
                "arm_group_type": "Active Comparator", 
                "description": "Gefitinib 250mg is Taken Orally everyday"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multi-center phase II randomized controlled study to assess the efficacy of\n      Gefitinib alone and Gefitinib combinating with Pemetrexed/cisplatin on patients with brain\n      metastasis from non-small cell lung cancer(NSCLC) harboring EGFR mutation type by\n      intracranial PFS(iPFS),also PFS ,DCR and OS.The side effect is evaluated as well."
        }, 
        "brief_title": "Gefitinib With or Without Pemetrexed/Cisplatin in Brain Metastases From Non-small Cell Lung Cancer", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Non-small Cell Lung Cancer", 
            "Brain Metastases", 
            "EGFR"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms", 
                "Neoplasm Metastasis", 
                "Neoplasms, Second Primary", 
                "Brain Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patient who was confirmed stage IV NSCLC with EGFR activating mutation and brain\n             metastases by pathologic histology or cytology\n\n          2. Patients who had never received therapy (including chemotherapy,WBRT,EGFR-TKI and\n             EGFR monoclonal antibody) after diagnosed brain metastases\n\n          3. Appraisable disease, the presence of at least three lesions if longest diameter <10\n             mm by brain MRI\n\n          4. Adult patients (\u2265 18 years and \u226475 years). ECOG Performance Status 0 or 1 Life\n             expectancy of at least 12 weeks.,Haemoglobin \u00b3 10.0 g/dl, Absolute neutrophil count\n             (ANC) \u00b31.5 x 109/L, platelets \u00b3 100 x 109/L. Total bilirubin \u00a3 1.5 x upper limit of\n             normal (ULN). ALT and AST < 2.5 x ULN in the absence of liver metastases, or < 5 x\n             ULN in case of liver metastases. Creatinine clearance \u00b3 60ml/min (calculated\n             according to Cockcroft-gault formula).\n\n          5. Patients should be contraceptive during the period of the trial until 8 weeks after\n             the last administration of icotinib.\n\n          6. Able to comply with the required protocol and follow-up procedures, and able to\n             receive oral medications.\n\n        Exclusion Criteria:\n\n          1. Patient was received irradiation of brain. Patient with meningeal metastases were\n             confirmed by MRI or cytology test of cerebrospinal fluid.\n\n          2. Patient is received the treatment of Phenytoin, carbamazepine, rifampicin,\n             phenobarbital, or St. John's Wort.\n\n          3. Patient was received EGFR Tyrosine Kinase Inhibitor or EGFR monoclonal antibody.\n\n          4. Interstitial pneumonia.Pericardial effusion, pleural effusion is uncontrolled .\n\n          5. Any unstable systemic disease (including active infection, uncontrolled hypertension,\n             unstable angina, congestive heart failure, myocardial infarction within the previous\n             year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic\n             disease).\n\n          6. Any significant ophthalmologic abnormality ,especially severe dry eye syndrome\n             ,keratoconjunctivitis sicca,Sjogren syndrome,severe exposure keratitis or any other\n             disorder likely to increase the risk of corneal epithelial lesions.\n\n          7. Lack of physical integrity of the upper gastrointestinal tract, or malabsorption\n             syndrome, or inability to take oral medication, or have active peptic ulcer disease.\n\n          8. The symptoms of increased intracranial pressure are uncontrolled after dehydration\n             and cortisone treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "160", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01951469", 
            "org_study_id": "NSCLC brain metastasis 01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Gefitinib and Pemetrexed/cisplatin", 
                "description": "Gefitinib 250mg is Taken Orally on day 4-28,combined Pemetrexed/cisplatin chemotherapy on day 1-3, every 28 days", 
                "intervention_name": "Gefitinib and Pemetrexed/cisplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Gefitinib mono-therapy", 
                "description": "Gefitinib 250mg is Taken Orally everyday", 
                "intervention_name": "Gefitinib mono-therapy", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Pemetrexed", 
                "Gefitinib", 
                "Cisplatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 10, 2013", 
        "location": {
            "contact": {
                "email": "chenlk@sysucc.org.cn", 
                "last_name": "li-kun Chen, doctor", 
                "phone": "13798019964"
            }, 
            "facility": {
                "address": {
                    "city": "Guangzhou", 
                    "country": "China", 
                    "state": "Guangdong", 
                    "zip": "510060"
                }, 
                "name": "Sun Yat-sen University of Cancer Center"
            }, 
            "investigator": {
                "last_name": "li-kun Chen, doctor", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Multicenter Phase II Study of Gefitinib Mono-therapy or Gefitinib Combined With Pemetrexed/Cisplatin in Patients With Brain Metastases From Non-small Cell Lung Cancer Harboring EGFR Mutation", 
        "other_outcome": [
            {
                "measure": "PFS(Progression Free Survival)", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "OS(Overall Survival)", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }
        ], 
        "overall_contact": {
            "email": "chenlk@sysucc.org.cn", 
            "last_name": "li-kun Chen, MD", 
            "phone": "13798019964"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "comparing the difference of iPFS(intracranial progression free survival) in two arms", 
            "safety_issue": "Yes", 
            "time_frame": "3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01951469"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Sun Yat-sen University", 
            "investigator_full_name": "Li-kun Chen", 
            "investigator_title": "medical doctor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "comparing the difference of Response rate(CR&PR) and in two arms", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "source": "Sun Yat-sen University", 
        "sponsors": {
            "collaborator": {
                "agency": "Wu Jieping Medical Foundation", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Sun Yat-sen University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}